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Webtable 1: Cox proportional hazard models predicting the risk of a first major vascular event in 
participants allocated to control (model 1) or less statin (model 2) 
Parameter      Model 1 
     Statin vs. Control 
   Model 2 
    More vs. less statin 
            Hazard ratio (95% CI)        Hazard ratio (95% CI) 
A. Baseline characteristics 
Male gender 1.56 (1.45 - 1.69) 1.07  (0.98 - 1.16) 
Current smoker  1.43 (1.28 - 1.60) 1.27  (1.18 - 1.38) 
Age (per 10 years) § 1.41 (1.35 - 1.48) 1.12  (1.08 - 1.16) 
Natural logarithm of HDL (per 1 
lnmmol/L) § 0.69 (0.63 - 0.75) 0.76  (0.68 - 0.86) 
LDL (per 1 mmol/L) § 1.14 (1.11 - 1.18) 1.19  (1.13 - 1.25) 
Treatment for hypertension 1.23 (1.17 - 1.29) 1.15  (1.08 - 1.22) 
Systolic BP (per 20mmHg) § 1.18 (1.13 - 1.23)  
Diastolic BP (per 10mmHg) § 0.95 (0.93 - 0.97)  
Creatinine (per 50mol/L) §* 1.18 (1.12 - 1.23) 1.19  (1.10 - 1.28) 
History of MI 2.50 (2.23 - 2.81) 1.19  (1.07 - 1.32) 
History of other CHD, but no MI  1.83 (1.69 - 1.97)  
History of stroke 1.35 (1.25 - 1.46) 1.48  (1.33 - 1.64) 
History of PAD 1.24 (1.16 - 1.32) 1.38  (1.24 - 1.54) 
Other/nonspecific vascular disease 
history† 1.22 (1.06 - 1.42)  
History of diabetes mellitus 1.53 (1.45 - 1.62) 1.40  (1.29 - 1.51) 
B. Interaction terms # 
Age and history of MI (per 10 years) 0.74 (0.70 - 0.79)  
Age and history of other CHD (per 
10 years) 0.77 (0.71 - 0.83)  
Systolic BP and history of MI 0.91 (0.86 - 0.95)  
Systolic BP and other CHD  0.89 (0.84 - 0.94)  
Current smoker and male gender 0.80 (0.71 - 0.9)  
Male gender and  history of MI 0.78 (0.70 - 0.87)  
C. Trial-specific terms (to model 
average risk) 
SSSS 1.95 (1.78 - 2.13)  
WOSCOPS 0.91 (0.79 - 1.04)  
CARE 1.25 (1.13 - 1.39)  
Post-CABG 0.88 (0.72 - 1.07)  
AFCAPS/TexCAPS 0.55 (0.47 - 0.65)  
LIPID 1.06 (0.98 - 1.15)  
GISSI-P 0.74 (0.59 - 0.92)  
ASCOT-LLA 0.65 (0.56 - 0.75)  
PROSPER 2.00 (1.80 - 2.22)  
CARDS 0.67 (0.55 - 0.81)  
ALERT 0.87 (0.73 - 1.04)  
ALLHAT-LLT 1.19 (1.07 - 1.32)  
LIPS 1.11 (0.87 - 1.42)  
ALLIANCE  1.51 (1.33 - 1.73)  
ASPEN  0.81 (0.67 - 0.97)  
4D 1.93 (1.63 - 2.28)  
MEGA 0.32 (0.26 - 0.39)  
JUPITER 0.48 (0.41 - 0.57)  
GISSI-HF 0.47 (0.37 - 0.60)  
AURORA  2.78 (2.46 - 3.14)  
HDL= high-density lipoprotein cholesterol. LDL= low-density lipoprotein cholesterol.  BP=blood pressure.  
CORONA 0.95 (0.79 - 1.16)  
A to Z  0.59  (0.40 - 0.86) 
PROVE-IT  1.76  (1.39 - 2.23) 
TNT  1.37  (1.24 - 1.51) 
IDEAL  1.21  (1.09 - 1.35) 
D. Trial and period-specific terms 
GISSI-P; months 0 to 6  4.27 (3.21 - 5.67)  
LIPS; months 0 to 6 4.00 (2.82 - 5.66)  
LIPS; months 7 to 12 2.96 (1.99 - 4.40)  
GISSI-HF; months 0 to 6  1.75 (1.20 - 2.56)  
A to Z; months 0 to 6  7.77  (5.03 - 12.02) 
A to Z; months 7 to 12  2.44  (1.51 - 3.95) 
PROVE-IT; months 0 to 6  3.78  (2.77 - 5.16) 
PROVE-IT; months 7 to 12  2.02  (1.46 - 2.79) 
TNT; months 0 to 6  1.41  (1.11 - 1.80) 
IDEAL; months 0 to 6  3.12  (2.48 - 3.93) 
IDEAL; months 7 to 12  1.39  (1.10 - 1.75) 
MI=myocardial infarction. CHD=coronary heart disease. PAD=peripheral arterial disease 
* missing creatinine values at randomisation in ASCOT were replaced with creatinine measured at screening; in 
AFCAPS/TexCAPS, AURORA and 4D creatinine data were either not available (AFCAPS/TexCAPS) or not relevant (dialysis 
patients in AURORA/4D) and so centred values of 0 were used 
 
§ centred around study mean 
 
†defined as history of myocardial infarction or stroke for ALLHAT; history of heart failure in GISSI-HF and CORONA; carotid 
artery disease, carotid stenosis 50%, carotid endarterectomy and abdominal aortic aneurysm in AURORA 
 
# interpretation of the effects of the separate characteristics in these interactions should be based both on relevant main effects 





Webtable 2:  Comparison of the observed (95% CI) and predicted rates of major vascular events in 
participating trials  
 
Study Duration (years)* Observed MVEs (%) (95% CI)† 
Average predicted 
MVEs (%) 
Statin vs. Control  
SSSS 5 33.8%  (31.8% - 35.8%) 33.7% 
WOSCOPS 5 10.0% (  8.9% - 11.1%) 10.1% 
CARE  5 27.3% (25.3% - 29.3%) 27.2% 
Post-CABG 5 22.9% (15.5% - 30.4%) 17.4% 
AFCAPS/TexCAPS 5 5.4% (  4.6% -   6.2%) 5.7% 
LIPID 5 22.4% (21.2% - 23.7%) 22.9% 
GISSI-P  2 11.1% (  9.7% - 12.4%) 10.9% 
HPS  5 19.5% (18.7% - 20.3%) 19.5% 
ASCOT-LLA 4 6.9% (  6.1% -   7.8%) 7.3% 
PROSPER 4 19.3% (17.6% - 21.0%) 20.2% 
CARDS 5 10.9% (  8.9% - 12.9%) 11.4% 
ALERT 5 12.5% (10.4% - 14.6%) 12.8% 
ALLHAT-LLT 5 16.1% (15.0% - 17.2%) 15.8% 
LIPS 4 27.3% (23.9% - 30.7%) 26.8% 
ALLIANCE 5 28.0% (25.1% - 30.9%) 27.6% 
ASPEN 4 12.3% (10.4% - 14.3%) 12.5% 
4D 5 39.9% (33.6% - 46.2%) 39.4% 
MEGA 5 3.2% (  2.7% -   3.8%) 3.2% 
JUPITER 5 5.3% (  4.2% -   6.5%) 4.9% 
GISSI-HF 5 9.4% (  7.9% - 10.8%) 10.6% 
AURORA 5 33.9% (30.7% - 37.1%) 34.7% 
CORONA 3 15.1% (13.5% - 16.7%) 15.3% 
More vs. Less statin  
A to Z 2 13.3% (11.8% - 14.8%) 13.3% 
PROVE-IT  2 22.6% (20.7% - 24.5%) 22.7% 
TNT  5 23.4% (22.2% - 24.6%) 23.4% 
IDEAL 5 25.8% (24.4% - 27.1%) 25.7% 
SEARCH 5 17.1% (16.2% - 18.1%) 17.2% 
Risk categories 
<5% 5 2.8% (  2.4% - 3.2%) 3.4% 
5%, <10% 5 7.4% (  6.9% - 7.9%) 7.3% 
10%, <20% 5 15.9% (15.5% - 16.4%) 15.4% 
20%, <30% 5 24.7% (24.0% - 25.3%) 24.3% 
30% 5 38.1% (37.0% - 39.2%) 38.1% 
MVE= major vascular event. 
*Duration over which rates of major vascular events compared: 5 years or the latest year with available Kaplan-Meier estimate of 
MVE within 50 days from end of that year. 
 




Webtable 3: Mean difference in plasma lipid concentrations at 1 year in participants at different 
levels of risk
 
Estimated 5-year risk of 









Statin vs. Control  
<5% -0.94 -0.88 0.034 -0.19 
5%, <10% -1.08 -0.96 0.031 -0.25 
10%, <20% -1.14 -0.99 0.045 -0.27 
20%, <30% -1.26 -1.10 0.032 -0.24 
30% -1.31 -1.21 0.034 -0.23 
Subtotal (22 trials) -1.22 -1.08 0.038 -0.26 
More vs. Less statin  
10%, <20%† -0.52 -0.44 0.006 -0.19 
20%, <30% -0.65 -0.53 -0.011 -0.24 
30% -0.70 -0.58 -0.013 -0.30 
Subtotal (5 trials) -0.61 -0.51 -0.005 -0.23 
 
LDL= low-density lipoprotein cholesterol. HDL= high-density lipoprotein cholesterol. 
 
* To convert values from mmol/L to mg/dL, divide triglycerides by 0.01129 and other lipids by 0.02586. 
 
In trials where the LDL-C at 1 year was missing (or >10mmol/L) the baseline value was assigned. In some studies, only a sub-
sample of participants were selected for 1 year blood samples: HPS (~4% of trial participants); SEARCH (~3% of participants). In 
other studies, no samples at 1 year were taken and so other blood samples were used: In A to Z and PROVE-IT, blood samples 
taken at 8 months were used; in ALLHAT samples taken at 2 years (from a random sample of 10% of participants randomised to 
pravastatin and 5% of participants randomised to usual care) were used. In ALLIANCE, lipid differences at 1 year in the usual 
care group were interpolated from those at baseline and final follow-up because the 1 year bloods were assayed in different 
laboratories depending on treatment allocation. 
 
Average values weighted by the trial and risk category-specific variances of the 'logrank' O minus E statistics for major vascular 
events. 
 
† Includes 141 participants (48 [4 MVEs] from A to Z and 93 [11 MVEs] from SEARCH) with an estimated 5-year risk of MVE   




Webtable 4: Eligibility of participants without prior vascular disease in each CTT risk category for 
statin therapy under current major guidelines  
 
CTT risk category 
(among participants without prior vascular disease) 
 Broad eligibility under current 
guidelines 
Estimated 5-





(% per annum)* 
Observed vascular 
death rate 
(% per annum)* 




<5% 0.2 0.1     
≥5%, <10% 0.8 0.3     
≥10%, <20% 1.6 1.0     
≥20%, <30% 3.2 2.3     
≥30% 5.6 5.8     
CTT= Cholesterol Treatment Collaboration. MCE= major coronary event, defined as non-fatal myocardial 
infarction or coronary death. * among placebo-allocated participants  
 
1. The Adult Treatment Panel III (ATP III) of the National Cholesterol Education program in the US recommends 
considering drug therapy for cholesterol modification for individuals without history of vascular disease but with 
multiple risk factors that confer a 10-year risk for major coronary events (i.e. myocardial infarction and coronary death) 
>10% which is considered moderately high or high risk. Observed annual major coronary event rate was less than 1% in 
those allocated to control intervention in the two lowest risk categories in CTT and therefore these participants are 
ineligible for statin intervention under ATP III.   
 
Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of 
the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97. 
Grundy SM, Cleeman JI, Merz CNB et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program 
Adult Treatment Panel III Guidelines. Circulation 2004;110(2):227-39. 
 
2. The Fourth Joint Task Force of the European Society of Cardiology (ESC) and Other Societies on Cardiovascular 
Disease Prevention in Clinical Practice and the ESC/EAS Guidelines for the management of dyslipidaemias recommend 
consideration of statin treatment typically for individuals without known vascular disease but at estimated 10-year risk of 
a fatal atherosclerotic event (including heart attack, stroke, aneurysm of the aorta, or other) of at least 5%. Observed 
annual vascular death rate was less than 0.5% in those participants without vascular disease allocated to control 
intervention in the two lowest risk categories in CTT and therefore these participants are ineligible for statin intervention 
under The Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease 
Prevention in Clinical Practice. 
 
Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. 
Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical 
practice (constituted by representatives of nine societies and by invited experts). European Journal of Cardiovascular Prevention & 
Rehabilitation 2007;14:Suppl-113. 
Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O et al. ESC/EAS Guidelines for the management of 
dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European 
Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-818. 
 
3. The National Institute for Health and Clinical Excellence (NICE) in the National Health Service (NHS) in England and 
Wales recommends lipid modification drug therapy for individuals without known cardiovascular disease (CVD) who 
have 20% or greater 10-year risk of developing CVD (defined as myocardial infarction, CHD death, angina, stroke or 
transient ischemia). As no total CVD endpoint was available in CTT data, an approximate estimation of risk was carried 
out to allow interpretation. Total CVD was evaluated by multiplying observed vascular death rates within the risk 
categories by a factor of 3 to 4 (as indicated by the SCORE data). The total estimated 10-year CVD risk among those 
allocated to control intervention in the two lowest risk categories in CTT was less than 20% and therefore these 
participants are ineligible for statin intervention under NICE guidelines. 
 
Cooper A, Nherera L, Calvert N et al.  Clinical Guidelines and Evidence Review for Lipid Modification: cardiovascular risk 
assessment and the primary and secondary prevention of cardiovascular disease. London:National Collaborating Centre for Primary 
Care and Royal College of General Practitioners; 2008.  
Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O et al. ESC/EAS Guidelines for the management of 
dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European 
Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-818. 
Webfigure 1: Effects on major vascular events per 1.0 mmol/L reduction in LDL cholesterol at different 
levels of risk, by baseline age and gender
Events (% per annum)
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< 5%  110 (0.40)   145 (0.51) 0.69 (0.49 − 0.98)
≥ 5%,<10%  295 (1.03)   433 (1.53) 0.65 (0.54 − 0.79)
≥ 10%,<20% 1336 (2.81)  1615 (3.55) 0.74 (0.66 − 0.83)
≥ 20%,<30% 1410 (4.86)  1691 (5.88) 0.81 (0.74 − 0.90)
≥ 30%  780 (7.74)   963 (9.93) 0.81 (0.73 − 0.89)
< 5%   52 (0.35)    92 (0.64) 0.56 (0.35 − 0.89)
≥ 5%,<10%  212 (1.08)   295 (1.52) 0.70 (0.55 − 0.90)
≥ 10%,<20% 1380 (2.84)  1622 (3.38) 0.78 (0.70 − 0.87)
≥ 20%,<30% 1637 (4.58)  1993 (5.70) 0.81 (0.74 − 0.89)
≥ 30% 1116 (7.20)  1439 (9.65) 0.78 (0.71 − 0.85)
< 5%    5 (0.25)    17 (0.81) 0.37 (0.13 − 1.08)
≥ 5%,<10%   97 (1.43)   119 (1.82) 0.79 (0.56 − 1.10)
≥ 10%,<20%  898 (3.48)   958 (3.66) 0.90 (0.79 − 1.04)
≥ 20%,<30% 1061 (4.83)  1235 (5.87) 0.81 (0.72 − 0.91)
≥ 30%  891 (8.19)  1056 (9.96) 0.81 (0.71 − 0.91)
< 5%   78 (0.31)   119 (0.48) 0.57 (0.38 − 0.86)
≥ 5%,<10%  196 (1.25)   232 (1.48) 0.84 (0.64 − 1.10)
≥ 10%,<20%  956 (3.04)  1071 (3.36) 0.88 (0.77 − 1.00)
≥ 20%,<30%  680 (4.94)   750 (5.68) 0.88 (0.76 − 1.02)
≥ 30%  429 (8.33)   522 (10.41) 0.79 (0.67 − 0.94)
< 5%   89 (0.46)   135 (0.67) 0.66 (0.46 − 0.95)
≥ 5%,<10%  408 (1.04)   615 (1.60) 0.64 (0.55 − 0.75)
≥ 10%,<20% 2658 (2.94)  3124 (3.55) 0.76 (0.70 − 0.83)
≥ 20%,<30% 3428 (4.70)  4169 (5.83) 0.80 (0.75 − 0.85)
≥ 30% 2358 (7.53)  2936 (9.72) 0.79 (0.74 − 0.84)
Subtotal 3931 (2.75)  4847 (3.45) 0.77 (0.74 − 0.81) p<0.0001
Subtotal 4397 (3.28)  5441 (4.13) 0.78 (0.75 − 0.81) p<0.0001
Subtotal 2952 (4.37)  3385 (5.09) 0.83 (0.78 − 0.87) p<0.0001
Subtotal 2339 (2.57)  2694 (2.98) 0.84 (0.79 − 0.89) p<0.0001
















Difference in overall effect between men and women: χ1
2= 5.23 (p=0.02)




Webfigure 2: Effects on major vascular events per 1.0 mmol/L reduction in LDL cholesterol at different 
levels of risk, by baseline LDL cholesterol (mmol/L)
Events (% per annum)
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Trial− and LDL subgroup−specific LDL weights used in these subgroup analyses.
< 5%   75 (0.37)  132 (0.65) 0.55 (0.39 − 0.79)
≥ 5%,<10%  245 (1.00)  369 (1.54) 0.62 (0.50 − 0.76)
≥ 10%,<20% 2356 (3.01) 2686 (3.50) 0.76 (0.69 − 0.85)
≥ 20%,<30% 2438 (4.86) 2874 (5.87) 0.78 (0.71 − 0.86)
≥ 30% 1462 (8.54) 1671 (10.03) 0.83 (0.73 − 0.93)
< 5%   92 (0.38)  122 (0.50) 0.74 (0.48 − 1.13)
≥ 5%,<10%  359 (1.18)  478 (1.58) 0.75 (0.63 − 0.90)
≥ 10%,<20% 1258 (2.88) 1509 (3.50) 0.82 (0.75 − 0.90)
≥ 20%,<30% 1670 (4.57) 2045 (5.72) 0.84 (0.78 − 0.90)
≥ 30% 1325 (6.85) 1787 (9.64) 0.78 (0.73 − 0.83)
Subtotal 6576 (3.46) 7732 (4.14) 0.77 (0.73 − 0.80) p<0.0001












Webfigure 3: Effects on non−fatal myocardial infarctions, CHD deaths and major coronary events per 1.0 mmol/L 
reduction in LDL cholesterol at different levels of risk
Events (% per annum)
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< 5%   38 (0.08)   79 (0.17) 0.46 (0.28 − 0.76)
≥ 5%,<10%  228 (0.41)  366 (0.67) 0.60 (0.49 − 0.74)
≥ 10%,<20% 1114 (0.88) 1404 (1.12) 0.73 (0.65 − 0.83)
≥ 20%,<30% 1241 (1.34) 1618 (1.77) 0.74 (0.67 − 0.82)
≥ 30%  980 (2.48) 1271 (3.27) 0.77 (0.71 − 0.85)
< 5%   14 (0.03)    9 (0.02) 1.60 (0.57 − 4.47)
≥ 5%,<10%   63 (0.11)   85 (0.15) 0.73 (0.47 − 1.11)
≥ 10%,<20%  582 (0.45)  635 (0.49) 0.84 (0.70 − 1.00)
≥ 20%,<30%  633 (0.66)  776 (0.81) 0.82 (0.71 − 0.95)
≥ 30%  610 (1.47)  785 (1.89) 0.77 (0.69 − 0.87)
< 5%   50 (0.11)   88 (0.19) 0.57 (0.36 − 0.89)
≥ 5%,<10%  276 (0.50)  435 (0.79) 0.61 (0.50 − 0.74)
≥ 10%,<20% 1644 (1.29) 1973 (1.57) 0.77 (0.69 − 0.85)
≥ 20%,<30% 1789 (1.93) 2282 (2.49) 0.77 (0.71 − 0.83)
≥ 30% 1471 (3.73) 1887 (4.86) 0.78 (0.72 − 0.84)
Overall 3601 (1.00) 4738 (1.33) 0.74 (0.71 − 0.77) p<0.0001
Overall 1902 (0.52) 2290 (0.62) 0.80 (0.76 − 0.85) p<0.0001












Webfigure 4: Effects on stroke subtypes per 1.0 mmol/L reduction in LDL cholesterol at different levels of risk
Events (% per annum)
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< 5%   45 (0.10)   60 (0.14) 0.69 (0.39 − 1.23)
≥ 5%,<10%  101 (0.23)  151 (0.34) 0.66 (0.49 − 0.90)
≥ 10%,<20%  479 (0.41)  549 (0.47) 0.84 (0.71 − 1.00)
≥ 20%,<30%  498 (0.56)  608 (0.69) 0.80 (0.68 − 0.94)
≥ 30%  373 (1.00)  466 (1.24) 0.81 (0.68 − 0.96)
< 5%   20 (0.05)   18 (0.04) 1.19 (0.42 − 3.36)
≥ 5%,<10%   25 (0.06)   23 (0.05) 1.01 (0.49 − 2.08)
≥ 10%,<20%   82 (0.07)   74 (0.07) 1.04 (0.68 − 1.59)
≥ 20%,<30%   91 (0.10)   71 (0.08) 1.26 (0.84 − 1.88)
≥ 30%   57 (0.15)   44 (0.12) 1.26 (0.75 − 2.12)
< 5%    6 (0.01)   12 (0.03) 0.53 (0.15 − 1.85)
≥ 5%,<10%   64 (0.11)   66 (0.12) 0.99 (0.60 − 1.61)
≥ 10%,<20%  236 (0.18)  284 (0.22) 0.84 (0.65 − 1.07)
≥ 20%,<30%  192 (0.21)  221 (0.24) 0.87 (0.68 − 1.12)
≥ 30%  141 (0.36)  151 (0.38) 0.92 (0.70 − 1.20)
Overall 1496 (0.45) 1834 (0.55) 0.79 (0.74 − 0.85) p<0.0001
Overall  275 (0.08)  230 (0.07) 1.15 (0.97 − 1.38) p= 0.11












Webfigure 5: Effects on major coronary events, strokes, coronary revascularisation procedures and major vascular 
events per 1.0 mmol/L reduction in LDL cholesterol at different levels of risk in the 22 statin vs control trials
Events (% per annum)







0.5 0.75 1 1.25 1.5




< 5%   50 (0.11)   88 (0.19) 0.57 (0.36 − 0.89)
≥ 5%,<10%  271 (0.49)  432 (0.79) 0.61 (0.50 − 0.74)
≥ 10%,<20%  949 (1.18) 1219 (1.54) 0.76 (0.69 − 0.85)
≥ 20%,<30% 1155 (1.93) 1526 (2.57) 0.78 (0.71 − 0.85)
≥ 30% 1080 (3.75) 1427 (5.12) 0.78 (0.72 − 0.84)
< 5%   71 (0.16)   90 (0.20) 0.74 (0.46 − 1.19)
≥ 5%,<10%  189 (0.34)  238 (0.43) 0.77 (0.60 − 0.98)
≥ 10%,<20%  578 (0.72)  677 (0.85) 0.85 (0.74 − 0.98)
≥ 20%,<30%  564 (0.95)  646 (1.08) 0.87 (0.76 − 1.00)
≥ 30%  436 (1.54)  484 (1.73) 0.88 (0.76 − 1.01)
< 5%   73 (0.16)  135 (0.30) 0.52 (0.35 − 0.75)
≥ 5%,<10%  221 (0.40)  340 (0.62) 0.63 (0.51 − 0.79)
≥ 10%,<20%  879 (1.10) 1090 (1.39) 0.77 (0.68 − 0.86)
≥ 20%,<30% 1289 (2.21) 1602 (2.77) 0.82 (0.75 − 0.89)
≥ 30%  757 (2.67) 1002 (3.65) 0.77 (0.70 − 0.85)
< 5%  167 (0.38)  254 (0.56) 0.62 (0.47 − 0.81)
≥ 5%,<10%  596 (1.09)  840 (1.56) 0.69 (0.60 − 0.79)
≥ 10%,<20% 2133 (2.74) 2566 (3.37) 0.80 (0.74 − 0.86)
≥ 20%,<30% 2607 (4.63) 3175 (5.73) 0.83 (0.78 − 0.88)
≥ 30% 1940 (7.23) 2422 (9.48) 0.80 (0.75 − 0.85)
Overall 3505 (1.30) 4692 (1.76) 0.76 (0.73 − 0.79) p<0.0001
Overall 1838 (0.68) 2135 (0.80) 0.85 (0.81 − 0.90) p<0.0001
Overall 3219 (1.21) 4169 (1.58) 0.77 (0.74 − 0.80) p<0.0001















Webfigure 6: Effects on major coronary events, strokes, coronary revascularisation procedures and major vascular
events per 1.0 mmol/L reduction in LDL cholesterol at different levels of risk in the 5 trials of more vs less statin
Events (% per annum)
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*Includes 141 participants (48 from A to Z and 93 from SEARCH) with an estimated 5−year risk of MVE less than 10%.
≥ 10%,<20%*  700 (1.49)  757 (1.61) 0.79 (0.57 − 1.10)
≥ 20%,<30%  634 (1.92)  756 (2.35) 0.68 (0.52 − 0.89)
≥ 30%  391 (3.67)  460 (4.19) 0.80 (0.59 − 1.09)
≥ 10%,<20%*  220 (0.46)  232 (0.49) 0.90 (0.51 − 1.59)
≥ 20%,<30%  217 (0.65)  254 (0.77) 0.69 (0.44 − 1.09)
≥ 30%  135 (1.23)  177 (1.56) 0.70 (0.42 − 1.18)
≥ 10%,<20%*  830 (1.82)  973 (2.15) 0.66 (0.51 − 0.86)
≥ 20%,<30%  917 (2.92) 1115 (3.68) 0.66 (0.54 − 0.81)
≥ 30%  503 (4.98)  653 (6.40) 0.65 (0.51 − 0.84)
≥ 10%,<20%* 1489 (3.35) 1636 (3.71) 0.75 (0.61 − 0.92)
≥ 20%,<30% 1501 (4.93) 1744 (5.95) 0.70 (0.59 − 0.83)
≥ 30%  847 (8.79) 1036 (10.74) 0.72 (0.59 − 0.88)
Overall 1725 (1.90) 1973 (2.19) 0.74 (0.65 − 0.85) p<0.0001
Overall  572 (0.62)  663 (0.72) 0.74 (0.59 − 0.92) p= 0.007
Overall 2250 (2.58) 2741 (3.20) 0.66 (0.60 − 0.73) p<0.0001















Webfigure 7: Effects on major coronary events per 1.0 mmol/L reduction in LDL cholesterol at different levels of 
risk, by history of vascular disease
Events (% per annum)
RR (CI) per 1.0 mmol/L reduction in LDL cholesterol Trend testStatin/more Control/less
5−year MVE risk
at baseline
Participants without vascular disease
Participants with vascular disease
All participants
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< 5%   47 (0.11)   80 (0.19) 0.59 (0.37 − 0.96)
≥ 5%,<10%  238 (0.50)  394 (0.83) 0.58 (0.48 − 0.72)
≥ 10%,<20%  447 (1.29)  557 (1.61) 0.78 (0.65 − 0.93)
≥ 20%,<30%  173 (2.51)  217 (3.15) 0.80 (0.60 − 1.06)
≥ 30%   79 (4.52)   91 (5.64) 0.76 (0.50 − 1.17)
< 5%    3 (0.14)    8 (0.37) 0.41 (0.09 − 1.76)
≥ 5%,<10%   38 (0.50)   41 (0.55) 0.86 (0.49 − 1.50)
≥ 10%,<20% 1197 (1.30) 1416 (1.56) 0.76 (0.67 − 0.86)
≥ 20%,<30% 1616 (1.88) 2065 (2.44) 0.77 (0.70 − 0.83)
≥ 30% 1392 (3.69) 1796 (4.82) 0.78 (0.72 − 0.84)
< 5%   50 (0.11)   88 (0.19) 0.57 (0.36 − 0.89)
≥ 5%,<10%  276 (0.50)  435 (0.79) 0.61 (0.50 − 0.74)
≥ 10%,<20% 1644 (1.29) 1973 (1.57) 0.77 (0.69 − 0.85)
≥ 20%,<30% 1789 (1.93) 2282 (2.49) 0.77 (0.71 − 0.83)
≥ 30% 1471 (3.73) 1887 (4.86) 0.78 (0.72 − 0.84)
Subtotal  984 (0.73) 1339 (1.00) 0.71 (0.65 − 0.77) p<0.0001
Subtotal 4246 (1.88) 5326 (2.39) 0.77 (0.74 − 0.80) p<0.0001















Webfigure 8: Effects on cause−specific mortality per 1.0 mmol/L reduction in LDL cholesterol at different levels of risk
Events (% per annum)
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*Includes 488 (statin/more statin) vs 548 (control/less statin) deaths of unknown cause
< 5%   14 (0.03)    9 (0.02) 1.60 (0.57 − 4.47)
≥ 5%,<10%   63 (0.11)   85 (0.15) 0.73 (0.47 − 1.11)
≥ 10%,<20%  582 (0.45)  635 (0.49) 0.84 (0.70 − 1.00)
≥ 20%,<30%  633 (0.66)  776 (0.81) 0.82 (0.71 − 0.95)
≥ 30%  610 (1.47)  785 (1.89) 0.77 (0.69 − 0.87)
< 5%   51 (0.11)   64 (0.14) 0.79 (0.47 − 1.32)
≥ 5%,<10%  172 (0.31)  185 (0.33) 0.90 (0.68 − 1.20)
≥ 10%,<20%  578 (0.45)  623 (0.48) 0.91 (0.78 − 1.05)
≥ 20%,<30%  688 (0.72)  763 (0.80) 0.91 (0.80 − 1.03)
≥ 30%  466 (1.12)  486 (1.17) 0.98 (0.83 − 1.14)
< 5%   10 (0.02)   13 (0.03) 0.77 (0.25 − 2.35)
≥ 5%,<10%   42 (0.07)   37 (0.07) 1.12 (0.62 − 2.03)
≥ 10%,<20%  170 (0.13)  180 (0.14) 0.90 (0.67 − 1.22)
≥ 20%,<30%  152 (0.16)  165 (0.17) 0.94 (0.71 − 1.25)
≥ 30%  147 (0.35)  138 (0.33) 1.08 (0.81 − 1.45)
< 5%    4 (0.01)    6 (0.01) 0.64 (0.12 − 3.45)
≥ 5%,<10%   33 (0.06)   23 (0.04) 1.48 (0.73 − 3.00)
≥ 10%,<20%  143 (0.11)  153 (0.12) 0.88 (0.63 − 1.22)
≥ 20%,<30%  123 (0.13)  129 (0.14) 0.94 (0.68 − 1.30)
≥ 30%  117 (0.28)  124 (0.30) 0.96 (0.69 − 1.32)
< 5%   79 (0.18)   92 (0.20) 0.87 (0.58 − 1.31)
≥ 5%,<10%  310 (0.55)  330 (0.59) 0.92 (0.74 − 1.13)
≥ 10%,<20% 1473 (1.14) 1591 (1.23) 0.88 (0.79 − 0.97)
≥ 20%,<30% 1596 (1.67) 1833 (1.92) 0.88 (0.81 − 0.96)
≥ 30% 1340 (3.23) 1533 (3.69) 0.87 (0.80 − 0.95)
< 5%  116 (0.26)  101 (0.22) 1.16 (0.80 − 1.68)
≥ 5%,<10%  270 (0.48)  309 (0.55) 0.88 (0.71 − 1.09)
≥ 10%,<20% 1054 (0.81) 1104 (0.86) 0.94 (0.83 − 1.07)
≥ 20%,<30%  963 (1.01)  941 (0.99) 1.00 (0.89 − 1.13)
≥ 30%  681 (1.64)  705 (1.70) 0.96 (0.83 − 1.10)
< 5%  232 (0.52)  244 (0.54) 0.97 (0.76 − 1.24)
≥ 5%,<10%  639 (1.14)  710 (1.27) 0.89 (0.77 − 1.03)
≥ 10%,<20% 2651 (2.04) 2827 (2.19) 0.91 (0.84 − 0.98)
≥ 20%,<30% 2683 (2.80) 2903 (3.04) 0.92 (0.86 − 0.99)
≥ 30% 2165 (5.22) 2403 (5.78) 0.89 (0.83 − 0.96)
Overall 1902 (0.52) 2290 (0.62) 0.80 (0.76 − 0.85) p<0.0001
Overall 1955 (0.53) 2121 (0.58) 0.92 (0.87 − 0.98) p= 0.006
Overall  521 (0.14)  533 (0.15) 0.98 (0.86 − 1.10) p= 0.69
Overall  420 (0.11)  435 (0.12) 0.95 (0.83 − 1.09) p= 0.48
Overall 4798 (1.30) 5379 (1.47) 0.88 (0.84 − 0.91) p<0.0001
Overall 3084 (0.84) 3160 (0.86) 0.96 (0.92 − 1.01) p= 0.16
























Webfigure 9: Effects on any deaths per 1.0 mmol/L reduction in LDL cholesterol at different levels of risk, 
by history of vascular disease and overall
Deaths (% per annum)
RR (CI) per 1.0 mmol/L reduction in LDL cholesterol Trend testStatin/more Control/less
5−year MVE risk
at baseline
Participants without vascular disease
Participants with vascular disease
All participants
179 (statin/more statin) vs 210 (control/less statin) deaths of unknown cause are included among participants without vascular disease.  
309 (statin/more statin) vs 338 (control/less statin) deaths of unknown cause are included among participants with vascular disease.
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< 5%  164 (0.38)  177 (0.41) 0.94 (0.71 − 1.26)
≥ 5%,<10%  372 (0.77)  446 (0.93) 0.83 (0.69 − 0.99)
≥ 10%,<20%  703 (1.99)  778 (2.19) 0.88 (0.76 − 1.02)
≥ 20%,<30%  363 (5.13)  339 (4.73) 1.06 (0.86 − 1.32)
≥ 30%  192 (10.76)  192 (11.44) 0.94 (0.70 − 1.25)
< 5%   68 (3.06)   67 (3.10) 1.04 (0.65 − 1.68)
≥ 5%,<10%  267 (3.48)  264 (3.50) 1.00 (0.80 − 1.26)
≥ 10%,<20% 1948 (2.07) 2049 (2.19) 0.92 (0.84 − 1.00)
≥ 20%,<30% 2320 (2.62) 2564 (2.91) 0.90 (0.84 − 0.97)
≥ 30% 1973 (4.97) 2211 (5.54) 0.89 (0.83 − 0.96)
< 5%  232 (0.52)  244 (0.54) 0.97 (0.76 − 1.24)
≥ 5%,<10%  639 (1.14)  710 (1.27) 0.89 (0.77 − 1.03)
≥ 10%,<20% 2651 (2.04) 2827 (2.19) 0.91 (0.84 − 0.98)
≥ 20%,<30% 2683 (2.80) 2903 (3.04) 0.92 (0.86 − 0.99)
≥ 30% 2165 (5.22) 2403 (5.78) 0.89 (0.83 − 0.96)
Subtotal 1794 (1.33) 1932 (1.42) 0.91 (0.85 − 0.97) p= 0.007
Subtotal 6576 (2.83) 7155 (3.09) 0.90 (0.87 − 0.93) p<0.0001
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Patientswithmissingbaselinecharacteristicsemployedintheriskmodelswereexcludedfromthe
estimationofmodels1and2,buttheirvalueswereimputedforthepurposeofpredicting5yearriskofa
majorvascularevent.Occasionalmissingage,gender,treatmentforhypertensionwereimputedusing
studyspecificmean(age)ormedian(gender,treatmentforhypertension).MissingdataforLDLC(1.7%),
HDLC(0.7%),bloodpressure(0.4%)andcreatinine(1.4%)wereimputedusingstudyspecificmeanvalues
byage,genderandtreatmentforhypertension.

Trialparticipantswerecategorisedintooneoffivebaselinecategoriesof5yearrisk:<5%;5to<10%;10to
<20%;20to<30%;and30%orlarger.Theproportionateandabsoluteeffectsofallocationtostatinor
morestatininterventiononspecificendpointswasthenestimatedseparatelywithineachofthese
subgroups(asdescribedinthemainstatisticalmethodssection).

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